CRON
Cronos Group Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.26
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 242.8M | 149.2M | 117.6M | 87.2M | 86.7M |
| Cost of Revenue | 161.4M | 87.5M | 92.4M | 75.3M | 71.3M |
| Gross Profit | 81.4M | 61.7M | 25.2M | 11.9M | 15.4M |
| Operating Expenses | |||||
| R&D Expense | 5.3M | 4.4M | 4.2M | 5.8M | 13.1M |
| SG&A Expense | 65.5M | 63.8M | 76.8M | 80.9M | 100.7M |
| General & Admin Expense | 41.2M | 42.0M | 55.2M | 58.2M | 82.7M |
| Selling & Marketing Expense | 24.3M | 21.8M | 21.6M | 22.7M | 18.0M |
| Other Expenses | (1.8M) | 11.3M | 20.7M | 9.9M | 13.0M |
| Total Operating Expenses | 69.0M | 79.5M | 101.7M | 96.7M | 126.9M |
| Cost and Expenses | 230.4M | 167.0M | 194.1M | 172.0M | 198.2M |
| Operating Income (EBIT) | 12.4M | (17.8M) | (76.5M) | (84.8M) | (111.4M) |
| Non-Operating | |||||
| Interest Income | 39.0M | 40.7M | 52.0M | 51.2M | 22.5M |
| Interest Expense | — | — | — | — | 13.0K |
| Net Interest Income | 39.0M | 40.7M | 52.0M | 51.2M | 22.5M |
| Other Non-Op Income/Expense | 55.8M | 419.2K | 113.1M | 11.1M | (9.6M) |
| Non-Operating Income (excl Interest) | (12.8M) | — | (17.0M) | (4.9M) | (7.0M) |
| EBT (Pre-Tax Income) | 68.2M | (17.4M) | 36.6M | (73.7M) | (121.0M) |
| Income Tax Expense | (10.8M) | (14.4M) | (3.4M) | (3.2M) | 34.2M |
| Bottom Line | |||||
| Net Income | 69.8M | (9.6M) | 41.1M | (74.0M) | (168.7M) |
| Earnings from Cont. Ops | 79.0M | (3.0M) | 40.0M | (70.4M) | (155.2M) |
| Earnings from Discont. Ops | — | — | — | (4.1M) | (13.6M) |
| Bottom Line Net Income | 69.8M | (9.6M) | 41.1M | (74.0M) | (168.7M) |
| Per Share | |||||
| Basic EPS | $0.18 | ($0.03) | $0.11 | ($0.19) | ($0.45) |
| Diluted EPS | $0.18 | ($0.03) | $0.11 | ($0.19) | ($0.45) |
| Revenue Per Share | $0.63 | $0.39 | $0.31 | $0.23 | $0.23 |
| Shares | |||||
| Basic Shares Outstanding | 385.3M | 385.3M | 382.1M | 381.0M | 377.0M |
| Diluted Shares Outstanding | 385.3M | 385.3M | 385.6M | 381.0M | 377.0M |
| Profitability Metrics | |||||
| EBITDA | 24.4M | (3.4M) | (50.2M) | (71.8M) | (91.3M) |
| D&A | (868.6K) | 14.5M | 9.3M | 8.1M | 13.1M |
| EBIT | 25.2M | (17.8M) | (59.5M) | (79.9M) | (104.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026